Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
التنسيق:	Artigo
اللغة:	الإنجليزية
منشور في:	2011
الوصول للمادة أونلاين:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Predicting the outcome of ankylosing spondylitis therapy
حسب: Vastesaeger, Nathan, وآخرون
منشور في: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
حسب: Bert Vander Cruyssen, وآخرون
منشور في: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
حسب: van der Heijde, Désirée, وآخرون
منشور في: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
حسب: Désirée van der Heijde, وآخرون
منشور في: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
حسب: Braun, Jürgen, وآخرون
منشور في: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
حسب: Jürgen Braun, وآخرون
منشور في: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
حسب: Wagner, Carrie, وآخرون
منشور في: (2011)

Ankylosing spondylitis: an overview
حسب: Joachim Sieper, وآخرون
منشور في: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
حسب: Deodhar, Atul, وآخرون
منشور في: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
حسب: Atul Deodhar, وآخرون
منشور في: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
حسب: Braun, J, وآخرون
منشور في: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
حسب: Désirée van der Heijde, وآخرون
منشور في: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
حسب: Dominique Baeten, وآخرون
منشور في: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
حسب: Jürgen Braun, وآخرون
منشور في: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
حسب: Jürgen Braun, وآخرون
منشور في: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
حسب: Jürgen Braun, وآخرون
منشور في: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
حسب: Inman, Robert D., وآخرون
منشور في: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
حسب: Xenofon Baraliakos, وآخرون
منشور في: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
حسب: Braun, Jürgen, وآخرون
منشور في: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
حسب: Jürgen Braun, وآخرون
منشور في: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
حسب: Cruyssen, Bert Vander, وآخرون
منشور في: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
حسب: Bert Vander Cruyssen, وآخرون
منشور في: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
حسب: Annelies Boonen, وآخرون
منشور في: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
حسب: Braun, Jürgen, وآخرون
منشور في: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
حسب: Sambrook, Philip N., وآخرون
منشور في: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
حسب: Philip N. Sambrook, وآخرون
منشور في: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
حسب: Braun, Jürgen, وآخرون
منشور في: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
حسب: Zochling, J, وآخرون
منشور في: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
حسب: Désirée van der Heijde, وآخرون
منشور في: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
حسب: Ben A. C. Dijkmans, وآخرون
منشور في: (2009)

Ankylosing spondylitis: an overview
حسب: Sieper, J, وآخرون
منشور في: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
حسب: Sudha Visvanathan, وآخرون
منشور في: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
حسب: Braun, J, وآخرون
منشور في: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
حسب: Jürgen Braun, وآخرون
منشور في: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
حسب: Davis, J C, وآخرون
منشور في: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
حسب: Désirée van der Heijde, وآخرون
منشور في: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
حسب: Braun, J, وآخرون
منشور في: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
حسب: Désirée van der Heijde, وآخرون
منشور في: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
حسب: Vosse, D, وآخرون
منشور في: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
حسب: Jürgen Braun, وآخرون
منشور في: (2016)